[ad_1]
An analysis of data from the phase 3 trial of the vaccine against COVID-19
From Russia (Sputnik V
) suggests that a two-dose regimen is 91.6% effective against symptomatic disease; a protection that in people over 60 is very similar and rises to 91.8%.
The preliminary results, published in “The Lancet”
, are based on the analysis of data from nearly 20,000 participants, of whom three-quarters received the vaccine and a quarter a placebo.
Here some data extracted from the official website
of the Russian vaccine ..
- This vaccine can be shipped and stored in a standard freezer and it is stable for long periods of time at 4 ° Celsius. This means that the vaccine can be widely available without the need for expensive specialized equipment.
- A vaccine efficacy of 91.6% has been determined based on data from 19,866 volunteers who received the first and second injections of the vaccine. Sputnik V or a placebo; 78 confirmed cases of COVID-19 were registered in the final control stage.
- The cost of a dose of Sputnik vaccine pFor foreign markets it will be less than $ 10.
- The vaccine It is given in two doses.
- More than 50 countries have requested the vaccination of more than 1.2 billion people with Sputnik V.
- The vaccine is named after the first Soviet space satellite. The launch of Sputnik-1 in 1957 he intensified space research around the world, creating the so-called “Sputnik moment” for the international community.
- Vaccine based on adenoviral vectors. The “vectors” are vehicles that can introduce genetic material from another virus into a cell. The adenovirus gene, which is the cause of the infection, is removed and a gene encoding the protein of another virus is inserted in its place. The inserted element is safe for the body and helps the immune system to react and produce antibodies that protect us from infection.
- Sputnik V It is the first vaccine registered in the world based on a proven platform based on human adenoviral vectors. The “Sputnik V” vaccine has already been registered in 17 countries.
- More than 31,000 volunteers participate in the post-registration clinical trial of “Sputnik V” in Russia
- The lyophilized (dry) form of the vaccine can be stored between +2 and +8 degrees Celsius, which facilitates its distribution to the whole world, including regions with difficult access.
[ad_2]
